Agena Bioscience in the News

Agena Bioscience and Heartgenetics Announce Co-Marketing Alliance

18 July 2017

HEARTDECODE® Software and Assays Designed for Use with the MassARRAY® DX System San Diego, CA, July 18, 2017– Agena Bioscience today announced a co-promotion agreement leveraging its MassARRAY® DX clinical diagnostics technology with HeartGenetics’ CE-IVD marked products for cardiovascular testing. The MassARRAY DX, a CE-IVD marked system, provides a streamlined... Read More

Agena Bioscience and Intermountain Healthcare Announce Research Collaboration to Advance Precision Medicine

12 July 2017

SAN DIEGO, CA, AND SAINT GEORGE, UTAH – Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue... Read More

Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe

29 June 2017

MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe SAN DIEGO, Calif., June 29, 2017– Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in... Read More

Agena Bioscience Announces Expanded Partnership With Assurex Health

20 June 2017

MassARRAY® System Selected for Assurex Health’s GeneSight Test SAN DIEGO, Calif., June 20, 2017– Agena Bioscience today announced that Assurex Heath, a wholly owned subsidiary of Myriad Genetics, Inc., has selected the MassARRAY® System for streamlined laboratory set-up and sample processing of Assurex Health’s GeneSight test. The GeneSight Psychotropic test... Read More

Agena Bioscience Introduces New Lung and Colon Cancer Panels for Detection of Somatic Mutations from Liquid Biopsies and Solid Tumor Tissues

15 March 2017

SAN DIEGO, Calif., March 15, 2017 — Agena Bioscience today introduced new targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSEEK™ Lung and Colon Panels enable detection of mutations as low as 0.1% minor allele frequency (MAF) from circulating tumor cells (CTCs)... Read More

Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY^® System

9 February 2017

SAN DIEGO, Calif., February 9, 2017 – Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer. While Fluorescence In Situ Hybridization (FISH) is the gold standard... Read More

Agena Bioscience Names Genelex as Certified Service Provider for Targeted Genetic Analysis

29 August 2016

SAN DIEGO, Calif., August 29, 2016 — Agena Bioscience today announced the successful certification of Genelex as a Certified Service Provider of the MassARRAY® technology. The MassARRAY System is used to identify and validate SNPs, INDELs, CNV’s, translocations, somatic mutations, including rare variants, and methylation profiles across a variety... Read More

David Coorey Joins Agena Bioscience to Lead Europe, Middle East, and Africa Business

11 July 2016

SAN DIEGO, Calif., July 11, 2016 — Agena Bioscience today announced the appointment of David Coorey as Vice President and Managing Director, EMEA. David joins Agena Bioscience from Becton Dickinson, where he most recently held the position of Business Unit Director for the Diagnostic Systems Division. David brings over 20... Read More

Agena Bioscience Launches High Sensitivity and Multiplexed Genetic Testing Product for Targeted Analysis of Solid Tumors

18 April 2016

iPLEX® HS chemistry enables multiplex detection down to 1% allele frequency SAN DIEGO, Calif., April 18, 2016 — Today Agena Bioscience announced the commercial availability of iPLEX® HS, a new chemistry that enables highly sensitive, multiplexed detection of genetic variants present in solid tumors. iPLEX HS, unveiled today at... Read More

Agena Bioscience Launches in vitro Diagnostic Tests for Lung and Colon Cancer in Europe

4 April 2016

Company achieves CE-IVD mark and enters routine molecular diagnostics market SAN DIEGO, Calif. and Hamburg, Germany, April 4, 2016 — Agena Bioscience today announced the launch of its CE-IVD marked MassARRAY® Dx products in Europe. Two targeted diagnostic panels will be sold, the MassARRAY Dx Lung Panel and the... Read More